Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2013 | Review Article

Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer

Authors: S. M. Schwarzenböck, J. Kurth, Ch. Gocke, T. Kuhnt, G. Hildebrandt, B. J. Krause

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2013

Abstract

Choline PET/CT has shown limitations for the detection of primary prostate cancer and nodal metastatic disease, mainly due to limited sensitivity and specificity. Conversely in the restaging of prostate cancer recurrence, choline PET/CT is a promising imaging modality for the detection of local regional and nodal recurrence with an impact on therapy management. This review highlights current literature on choline PET/CT for radiation treatment planning in primary and recurrent prostate cancer. Due to limited sensitivity and specificity in differentiating between benign and malignant prostatic tissues in primary prostate cancer, there is little enthusiasm for target volume delineation based on choline PET/CT. Irradiation planning for the treatment of single lymph node metastases on the basis of choline PET/CT is controversial due to its limited lesion-based sensitivity in primary nodal staging. In high-risk prostate cancer, choline PET/CT might diagnose lymph node metastases, which potentially can be included in the conventional irradiation field. Prior to radiation treatment of recurrent prostate cancer, choline PET/CT may prove useful for patient stratification by excluding distant disease which would require systemic therapy. In patients with local recurrence, choline PET/CT can be used to delineate local sites of recurrence within the prostatic resection bed allowing a boost to PET-positive sites. In patients with lymph node metastases outside the prostatic fossa and regional metastatic lymph nodes, choline PET/CT might influence radiation treatment planning by enabling extension of the target volume to lymphatic drainage sites with or without a boost to PET-positive lymph nodes. Further clinical randomized trials are required to assess treatment outcomes following choline-based biological radiation treatment planning in comparison with conventional radiation treatment planning.

Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.PubMedCrossRef

Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):16–22.PubMedCrossRef

De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol. 2005;75(3):325–33.PubMedCrossRef

Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72(3):799–807.PubMedCrossRef

van Lin EN, Futterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65(1):291–303.PubMedCrossRef

Thorwarth D, Leibfarth S, Mönnich D. Potential role of PET/MRI in radiotherapy treatment planning. Clin Transl Imaging. 2013;1(1):45–51.CrossRef

Picchio M, Giovannini E, Crivellaro C, Gianolli L, di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol. 2010;96(3):347–50.PubMedCrossRef

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.PubMedCrossRef

Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin. 2007;57(2):90–104.PubMedCrossRef

10.

Farsad M, Schwarzenbock S, Krause BJ. PET/CT and choline: diagnosis and staging. Q J Nucl Med Mol Imaging. 2012;56(4):343–53.PubMed

11.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol. 2002;42(1):18–23.PubMedCrossRef

12.

Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27(9):1415–9.PubMedCrossRef

13.

Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173(1):252–5.PubMedCrossRef

14.

Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47(2):262–9.PubMed

15.

Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 2006;47(8):1249–54.PubMed

16.

Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235(2):623–8.PubMedCrossRef

17.

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2004;31(3):317–24.PubMedCrossRef

18.

Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32(7):742–8.PubMedCrossRef

19.

Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46(10):1642–9.PubMed

20.

Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35(6):1065–73.PubMedCrossRef

21.

Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176(3):954–60; discussion 60.PubMedCrossRef

22.

Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34(1):45–53.PubMedCrossRef

23.

Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17(11):3751–9.PubMedCrossRef

24.

Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol. 2009;93(2):213–9.PubMedCrossRef

25.

Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T, et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol. 2010;186(11):600–6.PubMedCrossRef

26.

Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009;50(10):1585–93.PubMedCrossRef

27.

Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, et al. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol. 1998;159(3):915–9.PubMedCrossRef

28.

Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234(3):804–14.PubMedCrossRef

29.

Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14.PubMedCrossRef

30.

Seppala J, Seppanen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol. 2009;93(2):234–40.PubMedCrossRef

31.

Park H, Meyer CR, Wood D, Khan A, Shah R, Hussain H, et al. Validation of automatic target volume definition as demonstrated for 11C-choline PET/CT of human prostate cancer using multi-modality fusion techniques. Acad Radiol. 2010;17(5):614–23.PubMedCrossRef

32.

Chang JH, Joon DL, Lee ST, Gong SJ, Scott AM, Davis ID, et al. Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol. 2011;99(2):187–92.PubMedCrossRef

33.

Chang JH, Lim Joon D, Lee ST, Gong SJ, Anderson NJ, Scott AM, et al. Intensity modulated radiation therapy dose painting for localized prostate cancer using 11C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys. 2012;83(5):e691–6.PubMedCrossRef

34.

Bundschuh RA, Wendl C, Weirich G, Souvatzoglou M, Treiber U, Geinitz H, et al. Tumour volume delineation in prostate cancer assessed by [(11)C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2345-7.PubMed

35.

Ciernik IF, Brown DW, Schmid D, Hany T, Egli P, Davis JB. 3D-segmentation of the 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat. 2007;6(1):23–30.PubMed

36.

Niyazi M, Bartenstein P, Belka C, Ganswindt U. Choline PET based dose-painting in prostate cancer – modelling of dose effects. Radiat Oncol. 2010;5:23.PubMedCrossRef

37.

Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54(2):392–401.PubMedCrossRef

38.

Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol. 2006;176(5):2014–8; discussion 8–9.PubMedCrossRef

39.

Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):253–63.PubMedCrossRef

40.

Souvatzoglou M, Maurer T, Weirich G, Kuebler H, Treiber U. 11C-Choline PET/CT in staging of primary prostate cancer: A histological correlation of PET/CT findings with respect to nodal metastatic disease. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2.

41.

Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. 2011. doi:10.1016/j.urolonc.2010.08.008.PubMed

42.

Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50(9):1394–400.PubMedCrossRef

43.

Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(1):18–23.PubMedCrossRef

44.

Rischke HC, Knippen S, Kirste S, Grosu AL. Treatment of recurrent prostate cancer following radical prostatectomy: the radiation-oncologists point of view. Q J Nucl Med Mol Imaging. 2012;56(5):409–20.PubMed

45.

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035–41.PubMedCrossRef

46.

Picchio M, Alongi F, Giovacchini G, Di Rosa E, Cozzarini C, Landoni C, et al. 11C-Choline PET/CT image-guided radiotherapeutic treatment of lymph nodal recurrence in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2008;35:288.

47.

Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99(2):193–200.PubMedCrossRef

48.

Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97(1):49–55.PubMed

49.

Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44.PubMedCrossRef

50.

Geinitz H, Riegel MG, Thamm R, Astner ST, Lewerenz C, Zimmermann F, et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82(5):1930–7.PubMedCrossRef

51.

Swanson GP, Du F, Michalek JE, Hermans M. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen. Int J Radiat Oncol Biol Phys. 2011;80(1):62–8.PubMedCrossRef

52.

Souvatzoglou M, Kuebler H, Weirich G, Gschwend J, Schwaiger M, Krause BJ. 11C-Choline PET/CT in lymph node restaging of patients with relapse of prostate cancer undergoing salvage lymphadenectomy: comparison with histopathology. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 2.

53.

Schwarzenböck S, Protzel C, Heuschkel M, Kurth J, Hakenberg OW, Krause BJ. Dual-phase F-18 choline PET/CT positive lymph nodes in patients with recurrent prostate cancer and salvage lymphadenectomy – correlation with histopathology. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2.

54.

Wang H, Vees H, Miralbell R, Wissmeyer M, Steiner C, Ratib O, et al. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol. 2009;93(2):220–5.PubMedCrossRef

Title: Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer
Authors: S. M. Schwarzenböck
J. Kurth
Ch. Gocke
T. Kuhnt
G. Hildebrandt
B. J. Krause
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2404-0

At a glance: The STEP trials

Springer Medicine

Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2013

Functional and molecular imaging of localized and recurrent prostate cancer

Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer

Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

PET/MR in prostate cancer: technical aspects and potential diagnostic value

Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results

11C-Choline PET/CT and PSA kinetics